<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Xiao H</submitter><funding>Ministry of Science and Technology of the People&amp;apos;s Republic of China</funding><funding>National Natural Science Foundation of China</funding><funding>Natural Science Foundation of Guangdong Province</funding><pagination>1208-1222</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7379385</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>6(7)</volume><pubmed_abstract>Tumor-associated macrophages (TAMs) usually display the tumor-promoting M2 phenotype rather than the tumoricidal M1 phenotype. Thus, M2-to-M1 repolarization of TAMs has emerged as a promising strategy for tumor immunotherapy nowadays. However, immune side effects remain a great challenge, because phenotypic conversion of macrophages into the proinflammatory M1 phenotype may also be induced in normal tissue. Here, aiming at repolarizing TAMs without altering the M1/M2 polarization balance in healthy organs, we develop a micellar nanodrug with M2-targeting peptides (M2peptide) hidden in the pH-sheddable PEG corona so that an active targeting of M2-like macrophages is triggered only in the acidic tumor microenvironment (TME). The smart nanodrug effectively functions M2-to-M1 repolarization vi</pubmed_abstract><journal>ACS central science</journal><pubmed_title>M2-Like Tumor-Associated Macrophage-Targeted Codelivery of STAT6 Inhibitor and IKKβ siRNA Induces M2-to-M1 Repolarization for Cancer Immunotherapy with Low Immune Side Effects.</pubmed_title><pmcid>PMC7379385</pmcid><funding_grant_id>31971296</funding_grant_id><funding_grant_id>51933011</funding_grant_id><funding_grant_id>2014A030312018</funding_grant_id><funding_grant_id>2015CB755500</funding_grant_id><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Cheng D</pubmed_authors><pubmed_authors>Guo Y</pubmed_authors><pubmed_authors>Xiao H</pubmed_authors><pubmed_authors>Li B</pubmed_authors><pubmed_authors>Shuai X</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Han S</pubmed_authors></additional><is_claimable>false</is_claimable><name>M2-Like Tumor-Associated Macrophage-Targeted Codelivery of STAT6 Inhibitor and IKKβ siRNA Induces M2-to-M1 Repolarization for Cancer Immunotherapy with Low Immune Side Effects.</name><description>Tumor-associated macrophages (TAMs) usually display the tumor-promoting M2 phenotype rather than the tumoricidal M1 phenotype. Thus, M2-to-M1 repolarization of TAMs has emerged as a promising strategy for tumor immunotherapy nowadays. However, immune side effects remain a great challenge, because phenotypic conversion of macrophages into the proinflammatory M1 phenotype may also be induced in normal tissue. Here, aiming at repolarizing TAMs without altering the M1/M2 polarization balance in healthy organs, we develop a micellar nanodrug with M2-targeting peptides (M2peptide) hidden in the pH-sheddable PEG corona so that an active targeting of M2-like macrophages is triggered only in the acidic tumor microenvironment (TME). The smart nanodrug effectively functions M2-to-M1 repolarization vi</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jul</publication><modification>2025-06-01T02:54:41.032Z</modification><creation>2025-06-01T02:54:41.032Z</creation></dates><accession>S-EPMC7379385</accession><cross_references><pubmed>32724855</pubmed><doi>10.1021/acscentsci.9b01235</doi></cross_references></HashMap>